Online citations, reference lists, and bibliographies.
← Back to Search

A Prospective Analysis Of 18F-FDG PET/CT In Patients With Uveal Melanoma: Comparison Between Metabolic Rate Of Glucose (MRglu) And Standardized Uptake Value (SUV) And Correlations With Histopathological Features

Maria Lucia Calcagni, Maria Vittoria Mattoli, M. Blasi, G. Petrone, Maria Grazia Sammarco, L. Indovina, A. Mulé, V. Rufini, Alessandro Giordano
Published 2013 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
PurposeTo evaluate whether standardized uptake value (SUV) and/or metabolic rate of glucose (MRglu) are different among epithelioid, mixed, and spindle cell uveal melanomas, as well as between low and high risk melanomas; to correlate ultrasonographic data and metabolic parameters with histopathological features; and to assess the role of 18F-FDG PET/CT for evaluating prognosis.MethodsOf 34 eligible patients prospectively enrolled with clinical suspicion of medium/large uveal melanoma, 26 (15 men, mean age 62.8 ± 11.8 years) were evaluated. All patients underwent metastatic work-up, 3-D dynamic brain and whole-body 18F-FDG PET/CT, and surgery.ResultsOf the 26 ocular lesions, 23 showed 18F-FDG uptake, with a sensitivity of 88 %. MRglu was significantly higher in the epithelioid cell melanomas than in the spindle cell melanomas, as well as in high-risk lesions than in low-risk lesions (p = 0.01, p = 0.02, respectively). SUV and MRglu were correlated with histopathological features while ultrasonographic data were not.ConclusionMRglu is useful for distinguishing the different cell types in uveal melanoma, as well as high-risk from low-risk lesions, while SUV is not. MRglu provides a more accurate evaluation of glucose consumption, whereas SUV provides only an estimation. In addition, the metabolic parameters correlate with histopathological features, well also reflecting cellular behaviour in ocular malignancy. A longer follow-up is needed to assess the role of 18F-FDG in evaluating prognosis.
This paper references
[18F]-Fluorodeoxyglucose Positron Emission Tomography Computed Tomography로 진단된 전대동맥염에 의한 재발성 뇌경색
M. J. Kim (2010)
10.1016/j.ophtha.2007.12.015
Baseline echographic characteristics of tumors in eyes of patients enrolled in the Collaborative Ocular Melanoma Study: COMS report no. 29.
H. Boldt (2008)
10.1111/j.1346-8138.2005.tb00903.x
Factors Influencing [F‐18] 2‐Fluoro‐2‐Deoxy‐d‐Glucose (F‐18 FDG) Uptake in Melanoma Cells: The Role of Proliferation Rate, Viability, Glucose Transporter Expression and Hexokinase Activity
K. Yamada (2005)
10.1097/IAE.0b013e3181631937
THE RELATIONSHIP BETWEEN COMBINED POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY AND CLINICAL AND LIGHT MICROSCOPIC FINDINGS IN CHOROIDAL MELANOMA
L. Faia (2008)
10.1076/ceyr.27.2.69.15952
Molecular genetics of uveal melanoma
Amy E. Loercher (2003)
10.1007/s12149-009-0241-9
A recovery coefficient method for partial volume correction of PET images
S. Srinivas (2009)
10.1136/bjo.2005.069823
Whole body PET/CT for initial staging of choroidal melanoma
P. Finger (2005)
Requirements and implementation of a flexible kinetic modeling tool.
C. Burger (1997)
Standardized uptake values of FDG: body surface area correction is preferable to body weight correction.
C. Kim (1994)
10.1097/00004647-199807000-00002
Noninvasive Quantification of the Cerebral Metabolic Rate for Glucose Using Positron Emission Tomography, 18F-Fluoro-2-Deoxyglucose, the Patlak Method, and an Image-Derived Input Function
K. Chen (1998)
10.1136/bjo.2006.097949
18-Fluorine-labelled 2-deoxy-2-fluoro-d-glucose positron emission tomography/computed tomography standardised uptake values: a non-invasive biomarker for the risk of metastasis from choroidal melanoma
P. Finger (2006)
10.1001/archophthalmol.2009.208
Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes.
C. Shields (2009)
10.1016/S0360-3016(03)00006-3
The American Brachytherapy Society recommendations for brachytherapy of uveal melanomas.
S. Nag (2003)
10.1016/j.cpet.2007.10.002
Clinical and Research Applications of Quantitative PET Imaging.
S. Basu (2007)
10.1159/000050851
Value of Positron Emission Tomography in the Diagnosis of Malignant Ocular Tumors
C. Spraul (2001)
10.1097/IAE.0b013e3181835730
Bovine pericardium for scleral closure in transscleral local resection of choroidal melanoma.
A. Scupola (2008)
10.1001/ARCHOPHT.1951.01700010363009
Malignant melanoma of the uveal tract.
L. Lehrfeld (1951)
Malignant melanoma tumors of eye: study of histologic types in Ill cases
GR Callender (1931)
10.1080/02713680500478535
KI-67 Immunopositivity in Choroidal and Ciliary Body Melanoma with Respect to Nucleolar Diameter and Other Prognostic Factors
Rana'a T. Al-Jamal (2006)
10.1038/sj.eye.6702044
Visualization of primary uveal melanoma with PET/CT scan
A. Singh (2006)
10.5301/ejo.5000049
Initial PET/CT Staging for Choroidal Melanoma: AJCC Correlation and Second Nonocular Primaries in 333 Patients
A. Freton (2012)
10.1016/0002-9394(60)91659-7
Malignant melanoma of the uvea.
J. H. Scruggs (1960)
10.1097/ICU.0b013e328330b549
Update on posterior uveal melanoma: treatment of the eye and emerging strategies in the prognosis and treatment of metastatic disease
Y. Shildkrot (2009)
10.1136/bjo.2010.198085
Association of high metabolic activity measured by positron emission tomography imaging with poor prognosis of choroidal melanoma
C. Lee (2011)
10.1016/J.OPHTHA.2007.01.032
Incidence of uveal melanoma in Europe.
G. Virgili (2007)
10.1038/eye.2012.126
Progress in the management of patients with uveal melanoma. The 2012 Ashton Lecture
B. Damato (2012)
10.1016/j.ophtha.2012.01.045
Liver function testing is not helpful for early diagnosis of metastatic uveal melanoma.
F. Mouriaux (2012)
Low efficacy of 18F-FDG PET for detection of uveal malignant melanoma compared with 123I-IMP SPECT.
K. Kato (2006)
10.1136/bjo.81.3.240
Reassessment of the PAS patterns in uveal melanoma
A. J. Foss (1997)
10.1136/bjo.2005.066399
PET/CT imaging: detection of choroidal melanoma
S. Reddy (2005)
10.1016/S0169-5002(02)00221-0
PET imaging in patients with bronchioloalveolar cell carcinoma.
L. Heyneman (2002)
10.1097/00004728-199201000-00014
MRI, antibody-guided scintigraphy, and glucose metabolism in uveal melanoma.
G. Lucignani (1992)
10.1186/1756-8722-1-13
Relation between nodule size and 18F-FDG-PET SUV for malignant and benign pulmonary nodules.
Majid Khalaf (2008)
10.1016/S0002-9394(14)77914-0
Modifications of Callender's classification of uveal melanoma at the Armed Forces Institute of Pathology.
I. Mclean (1983)
10.1007/978-1-4757-3656-4
AJCC Cancer Staging Manual
M. B. Amin (2002)
10.1038/jcbfm.1985.24
Glucose Metabolic Rate Kinetic Model Parameter Determination in Humans: The Lumped Constants and Rate Constants for [18F]Fluorodeoxyglucose and [11C]Deoxyglucose
M. Reivich (1985)
10.1158/1078-0432.CCR-10-3169
Therapeutic Implications of the Emerging Molecular Biology of Uveal Melanoma
M. Patel (2011)
10.1097/00006231-199612000-00009
Glucose metabolism and pathological findings in uveal melanoma: preliminary results.
G. Modorati (1996)
10.1378/CHEST.06-0711
The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules.
C. Daniels (2007)
10.1097/IAE.0b013e3181b32f36
ASSOCIATION OF POSITIVE DUAL-MODALITY POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY IMAGING OF PRIMARY CHOROIDAL MELANOMA WITH CHROMOSOME 3 LOSS AND TUMOR SIZE
T. Mccannel (2010)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar